A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy. READ MORE
British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.
Researchers compared intensity-modulated radiation therapy versus conventional radiation therapy by evaluating acute toxicities in the GI and GU systems.
Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.
A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy.
A recent study assessed whether neoadjuvant chemotherapy is superior to primary debulking surgery with regard to mortality and quality of life for patients with advanced epithelial ovarian cancer.
A recent study found that treatment with PARP inhibitors significantly increases the risk of hematologic toxicities and warrants frequent clinical monitoring by clinicians.
ICER confirmed in a recent report that evidence is lacking for outcomes comparisons of PARP inhibitors to treat ovarian cancer, and that prices should be lowered to increase affordability and patient access.
Research in Review
High-grade serous ovarian cancer can be categorized in five molecular subtypes associated with survival and surgical outcomes.
New research questions the value of risk-reducing mastectomy within five years of ovarian cancer diagnosis in patients with BRCA mutations.
A tool for measuring blood flow and volume to ovarian cancer tumors accurately predicts the effectiveness of treatment.
Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival and overall survival than those without the antigen.
The American College of Obstetricians and Gynecologists has recently updated its clinical guidelines for the management of hereditary breast and ovarian cancer syndrome.